Package Leaflet: Information for the User
Rivaroxaban Bayer 15mg film-coated tablets EFG
Rivaroxaban Bayer 20mg film-coated tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the package leaflet
This medication contains the active ingredient rivaroxaban.
This medication is used in adults to:
This medication is used in children and adolescents under 18 years of age and with a body weight of 30 kg or more to:
This medication belongs to a group of medications called antithrombotic agents. It works by blocking a factor in the blood clotting process (factor Xa) and thus reducing the tendency of the blood to form clots.
Do not takeRivaroxaban Bayer
Do not takethis medicationand inform your doctorif any of these circumstances apply to you.
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medication.
Be particularly careful withRivaroxaban Bayer
Inform your doctorif you have any of these conditionsbefore taking this medication. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If you need surgery
Children and adolescents
Rivaroxaban Bayer tablets are not recommended in children with a body weight of less than 30kg.
There is not enough information about the use of this medication in children and adolescents for the indications in adults.
Other medications andRivaroxaban Bayer
Inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medication, including those purchased without a prescription.
If any of the above circumstances apply to you, inform your doctorbefore taking this medication, as the effect of this medication may be increased. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If your doctor considers that you have a higher risk of developing a stomach or intestinal ulcer, they may recommend that you also use a preventive treatment.
If any of the above circumstances apply to you,inform your doctorbefore taking this medication, as the effect of this medication may be reduced. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
Pregnancy and breastfeeding
Do not take this medication if you are pregnant or breastfeeding. If there is any possibility that you may become pregnant, use a reliable contraceptive while taking this medication. If you become pregnant while taking this medication, inform your doctor immediately, who will decide how you should be treated.
Driving and using machines
This medication may cause dizziness (frequent side effect) or fainting (uncommon side effect) (see section 4 "Possible side effects"). You should not drive, ride a bicycle, or use tools or machines if you are affected by these symptoms.
Rivaroxaban Bayercontains lactose and sodium
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains less than 1 mmol of sodium (23 mg) per tablet; this is, essentially "sodium-free".
Follow the instructions for administration of this medication exactly as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
You must take this medication with food.
Swallow the tablets, preferably with water.
If you have difficulty swallowing the tablet whole, consult your doctor about other ways to take this medication. The tablet can be crushed and mixed with water or apple sauce, immediately before taking it. Then, take food.
If necessary, your doctor may also administer the crushed rivaroxaban tablet through a gastric tube.
What dose to take
The recommended dose is one rivaroxaban 20 mg tablet once a day.
If you have kidney problems, the dose may be reduced to one rivaroxaban 15 mg tablet once a day.
If you need to undergo a procedure to treat blocked blood vessels in your heart (called percutaneous coronary intervention - PCI with stent insertion), there is limited evidence to reduce the dose to one rivaroxaban 15 mg tablet once a day (or to one rivaroxaban 10 mg tablet once a day if your kidneys do not function properly) in addition to an antiplatelet medication such as clopidogrel.
The recommended dose is one rivaroxaban 15 mg tablet twice a day for the first 3 weeks. For treatment after 3 weeks, the recommended dose is one rivaroxaban 20 mg tablet once a day.
After at least 6 months of treatment for blood clots, your doctor may decide to continue treatment with one 10 mg tablet once a day or one 20 mg tablet once a day.
If you have kidney problems and are taking one rivaroxaban 20 mg tablet once a day, your doctor may decide to reduce the treatment dose to one rivaroxaban 15 mg tablet once a day after 3 weeks if the risk of bleeding is higher than the risk of having another blood clot.
The dose of this medication depends on body weight and will be calculated by the doctor.
Take each dose of rivaroxaban with a drink (e.g., water or juice) during a meal. Take the tablets every day at approximately the same time. Consider setting an alarm to remind you.
For parents or caregivers: observe the child to ensure they take the entire dose.
Since the dose of rivaroxaban is based on body weight, it is important to attend scheduled visits with the doctor, as it may be necessary to adjust the dose as the weight changes.
Never adjust the dose of this medication on your own. Your doctor will adjust the dose if necessary.
Do not split the tablet to try to obtain a fraction of the tablet dose. If a smaller dose is required, please use the alternative rivaroxaban granule presentation for oral suspension.
In children and adolescents who cannot swallow whole tablets, please use rivaroxaban granules for oral suspension.
If the oral suspension is not available, you can crush the rivaroxaban tablet and mix it with water or apple sauce immediately before taking it. Take some food after taking this mixture. If necessary, your doctor may also administer the crushed rivaroxaban tablet through a gastric tube.
If you spit out the dose or vomit
Call your doctor if you spit out the dose or vomit repeatedly after taking this medication.
When to take Rivaroxaban Bayer
Take the tablets every day, until your doctor tells you to stop.
Try to take the tablets at the same time every day to remember when to take them.
Your doctor will decide how long you should continue taking the treatment.
To prevent blood clots in the brain (stroke) or in other blood vessels:
If you need to undergo a procedure to restore a normal heartbeat, called cardioversion, take this medication at the times indicated by your doctor.
If you forget to take Rivaroxaban Bayer
If you are taking one 20 mg or one 15 mg tablet oncea day, and you forget to take a dose, take it as soon as you remember. Do not take more than one tablet in a single day to make up for a forgotten dose. Take the next tablet the next day and, after that, continue taking one tablet every day.
If you are taking one 15 mg tablet twicea day, and you forget to take a dose, take it as soon as you remember. Do not take more than two 15 mg tablets in a single day. If you forget to take a dose, you can take two 15 mg tablets at the same time, for a total of two tablets (30 mg) in a day. The next day, you should continue taking one 15 mg tablet twice a day.
If you take more Rivaroxaban Bayer than you should
Call your doctor immediately if you have taken too many rivaroxaban tablets. Taking too much rivaroxaban increases the risk of bleeding.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you interrupt treatment with Rivaroxaban Bayer
Do not stop treatment with this medication without consulting your doctor first, as this medication treats and prevents serious conditions.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Like other similar medicines to reduce blood clot formation, this medicine can cause bleeding that can put the patient's life at risk. Excessive bleeding can cause a sudden drop in blood pressure (shock). In some cases, the bleeding may not be evident.
Tell your doctor immediately if you or your child experience any of the following symptoms:
Your doctor may decide to keep you under closer observation or change your treatment.
The frequency of these adverse effects is very rare (up to 1 in 10,000 people).
The frequencies of severe allergic reactions are very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic edema; may affect up to 1 in 100 people).
General list of possible adverse effects found in adults, children, and adolescents
Frequent(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Very Rare(may affect up to 1 in 10,000 people)
Frequency Not Known(frequency cannot be estimated from available data)
Adverse Effects in Children and Adolescents
In general, the adverse effects observed in children and adolescents treated with this medicine were similar to those observed in adults and their severity was mainly mild to moderate.
Adverse effects that were more frequently observed in children and adolescents:
Very Frequent(may affect more than 1 in 10 people)
Frequent(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the packaging and on each blister after "CAD" or "EXP".
The expiration date is the last day of the month indicated.
No special storage conditions are required.
Crushed Tablets
Crushed tablets are stable in water or apple puree for up to 4 hours.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE point in the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Rivaroxaban Bayer
Tablet core: microcrystalline cellulose, sodium croscarmellose, lactose monohydrate, hypromellose, sodium lauryl sulfate, magnesium stearate. See section 2 "Rivaroxaban Bayer contains lactose and sodium"
Tablet film coating: macrogol, hypromellose, titanium dioxide (E 171), red iron oxide (E 172).
Appearance of the Product and Package Contents
The film-coated tablets of Rivaroxaban Bayer 15 mg are round, red, biconvex, and bear the Bayer cross on one side, and "15" and a triangle on the other.
They are packaged
The film-coated tablets of Rivaroxaban Bayer 20 mg are round, brown-red, biconvex, and bear the Bayer cross on one side, and "20" and a triangle on the other.
They are packaged
Not all pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Bayer Hispania, S.L.
Av. Baix Llobregat, 3-5
08970 Sant Joan Despí (Barcelona)
Spain
Manufacturer
The manufacturer can be identified by the batch number printed on the side flap of the pack and on each blister:
Bayer AG
Kaiser-Wilhelm-Allee
51368 Leverkusen
Germany
Bayer HealthCare Manufacturing Srl.
Via delle Groane, 126
20024 Garbagnate Milanese
Italy
Bayer Bitterfeld GmbH
Ortsteil Greppin, Salegaster Chaussee 1
06803 Bitterfeld-Wolfen
Germany
This medicine is authorized in the Member States of the European Economic Area under the following names:
Germany, Austria, Denmark, Spain, France, Italy, Poland, Sweden: Rivaroxaban Bayer
Date of the Last Revision of this Leaflet:08/2023.
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).